Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area

BMC Psychiatry

Tor Ketil Larsen¹  Wenche ten Velden Hegelstad¹  Patrick D McGorry³  Jan Olav Johannessen⁴  Jørgen Bramness²  Inge Joa⁴  Melissa A Weibell¹ 

[1] Regional Centre for Clinical Research in Psychosis, TIPS, Stavanger University Hospital, Armauer Hansensvei, 4014 Stavanger, Norway;Norwegian Institute of Public Health, P.O. box 4404, 0403 Oslo, Norway;ORYGEN Research Centre, University of Melbourne, Locked bag 10, Parkville, Melbourne, VIC 3052, Australia;Faculty of Social Sciences, Institute of Health, University of Stavanger, Kjell Arholmsgt 41, 4021 Stavanger, Norway

关键词: Co-morbidity;    Incidence;    First–episode;    Substance-induced;    Substance misuse;    Psychosis;   

Others  :  1123877
DOI  :  10.1186/1471-244X-13-319

 received in 2013-05-23, accepted in 2013-11-18,  发布年份 2013

【 摘 要 】

Background

Substance misuse is a well-recognized co-morbidity to psychosis and has been linked to poor prognostic outcomes in patients. Researchers have yet to investigate the difference in rates and characteristics between first-episode Substance Induced Psychosis (SIP) and primary psychosis. We aimed at comparing patients with SIP to primary psychosis patients with or without substance misuse at baseline.

Methods

Thirty SIP patients, 45 primary psychosis patients with substance misuse (PS) and 66 primary psychosis patients without substance misuse (PNS) in a well-defined Norwegian catchment area were included from 2007–2011. Assessments included symptom levels (PANSS), diagnostic interviews (SCID), premorbid function scale (PAS) and global functioning (GAF f/s).

Results

Treated incidence for SIP was found to be 6.5/100 000 persons per year, 9.7/100 000 persons per year for PS and 24.1/100 000 persons per year for PNS (15-65 yrs). Patients who had substance misuse (PS and SIP) were more likely to be male. Duration of Untreated Psychosis (DUP) was significantly shorter in the SIP group (5.0 wks., p = 0.003) and these had more positive symptoms on the PANSS (p = 0.049). SIP patients also did poorer on early youth academic levels on the PAS.

Conclusions

Yearly treated incidence of SIP is 6.5/100 000 persons per year in a Norwegian catchment area. SIP patients have short DUPs, are more likely to be male, have more positive symptoms at baseline and poorer premorbid academic scores in early adolescence. Follow-up will evaluate stability of diagnosis and characteristics.

【 授权许可】

   
2013 Weibell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Satel SL, Edell WS: Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 1991, 148(12):1708-1711.
• [2]McKetin R, McLaren J, Lubman DI, Hides L: The prevalence of psychotic symptoms among metamphetamine users. Addiction 2006, 101:1473-1478.
• [3]Arendt M, Rosenberg R, Foldager L, Perto G, Munk-jorgensen P: Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005, 187:510-515.
• [4]Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse- results from the epidemiologic catchment area (EDC) study. J Am Med Assoc 1990, 264(19):2511-2518.
• [5]Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, Carr V, Morgan V, Korten A, Harvey C: Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust N Z J Psychiatry 2000, 34(2):221-236.
• [6]Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I, Harrison G: Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999, 174:150-153.
• [7]Barnett JH, Werners U, Secher SM, Hill K, Brazil R, Masson K, Pernet DE, Kirkbride JB, Murray GK, Bullmore ET, et al.: Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007, 190:515-520.
• [8]Hambrecht M, Häfner H: Sustance abuse and the onset of schizophrenia. Biol Psychiatry 1996, 40:1155-1163.
• [9]Sorbara F, Liraud F, Assens F, Abalan F, Verdoux H: Substance use and the course of early psychosis: a 2-year follow up of first-admitted subjects. Eur Psychiatry 2003, 18:133-136.
• [10]Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD: Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006, 189:229-234.
• [11]Wade D, Harrigan S, McGorry PD, Burgess PM, Whelan G: Impact of severity of substance use disorder on symptomatic and funcitonal outcome in young individuals with first-episode psychosis. J Clin Psychiatry 2007, 68(5):767-774.
• [12]Turkington A, Mulholland CC, Rushe TM, Anderson R, McCaul R, Barrett SL, Barr RS, Cooper SJ: Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry 2009, 195:242-248.
• [13]Addington J, Addington D: Patterns, prdictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007, 115:304-309.
• [14]González-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibáñez B, Haidar MK, Vieta E, Arango C: Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011, 37(3):631-639.
• [15]Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, Naber D, McGorry PD, Schimmelmann BG: The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005, 112(2):141-148.
• [16]Serper MR, Chou JC-Y, Allen MH, Czobor P, Cancro R: Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophr Bull 1999, 25(2):387-394.
• [17]Caton CLM, Drake RE, Hasin DS, Dominguez B, Shrout PE, Samet S, Schanzer B: Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Arch Gen Psychiatry 2005, 62:137-145.
• [18]Fraser S, Hides L, Philips L, Proctor D, Lubman DI: Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. Schizophr Res 2012, 136(1–3):110-115.
• [19]Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, Opjordsmoen S, Rund BR, Simonsen E, Vaglum P, et al.: Substance abuse in first-episode non-affective psychosis. Schizophr Res 2006, 88:55-62.
• [20]Sevy S, Robinson DG, Napolitano B, Patel RC, Gunduz-Bruce H, Miller R, McCormack J, Lorell BS, Kane J: Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophr Res 2012, 120:101-107.
• [21]Løberg E-M, Hugdahl K: Cannabis use and cognition in schizophrenia. Front Human Neurosci 2009, 3:1-8.
• [22]Ringen PA, Melle I, Birkenaes AB, Engh JA, Faerden A, Vaskinn A, Friis S, Opjordsmoen S, Andreassen OA: The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatr Scand 2008, 118:297-304.
• [23]Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G: Self reported cannabis use as a risk factor for schizophrenia in Swedis conscripts of 1969: historical cohort study. Br Med J 2002, 325:1199.
• [24]Arseneault L, Cannon M, Poulton R, Murrey R, Caspi A, Moffit TE: Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J 2002, 325:1212-1213.
• [25]WHO: The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organisation; 1992.
• [26]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: American Psychiatric Association; 2000.
• [27]Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Løberg E-M, Medhus S, Tanum L, Franck J: Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable. BMC Psychiatry 2012., 12doi: 10.1186/1471-244X-12-221
• [28]Arseneault L, Cannon M, Witton J, Murrey RM: Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004, 184:110-117.
• [29]Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-238.
• [30]Smith MJ, Thirtalli J, Abdallah AB, Murray RM, Cottler LB: Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry 2009, 50(3):245-250.
• [31]Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R: Clinical course and outomes of metamphetamine-dependent adults with psychosis. J Subst Abus Treat 2008, 35(4):445-450.
• [32]Crebbin K, Mitford E, Paxton R, Turkington D: First-episode drug-induced psychosis: a medium term follow up study reveals a high risk group. Soc Psychiatry Psychiatr Epidemiol 2009, 44:710-715.
• [33]Caton CLM, Hasin DS, Shrout PE, Drake RE, Dominguez B, First MB, Samet S, Schnauzer B: Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiatry 2007, 190:105-111.
• [34]Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen H-U, Os J: Prospective cohort study of cannabis use, predisposition for psychosis and psychotic symptoms in young people. Br Med J 2005, 330:11-14.
• [35]Harris D, Batki S: Stimulant psychosis: symptom profile and acute clinical course. Am J Addict 2000, 9(1):28-37.
• [36]Joa I, Johannessen JO, Auestad B, Friis S, McGlashan T, Melle I, Opjordsmoen S, Simonsen E, Vaglum P, Larsen TK: The key to reducing duration of untreated first psychosis: information campaigns. Schizophr Bull 2008, 34(3):466-472.
• [37]Statistics Norway: Population Data. 2011. http://statbank.ssb.no/statistikkbanken/Default_FR.asp?PXSid=0&nvl=true&PLanguage=0&tilside=selecttable/MenuSelS.asp&SubjectCode=02 webcite
• [38]Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, Simonsen E, Rund BR, Vaglum P, McGlashan TH: Reducing the duration of untreated psychosis in first episode psychosis. Arch Gen Psychiatry 2004, 61(2):143-150.
• [39]Larsen TK, Johannessen JO, McGlashan TH, Friis S, Guldberg C, Haahr U, Horneland M, Melle I, Opjordsmoen S, Simonsen E, et al.: Reducing duration fo untreated first psychosis: changes in patient characteristics at presentation. Am J Psychiatr 2001, 158(11):1917-1919.
• [40]Johannessen JO, Larsen TK, Joa I, Melle I, Friis S, Opjordsmoen S, Lund BR, Simonsen E, Vaglum P, McGlashan T: Pathways to care for first-episode psychosis in an early detection healthcare sector. Part of the Scandinavian TIPS study. Br J Psychiatry 2005, 187:24-28.
• [41]First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clincial Interview for DSM-IV Axis I Disorders-Patient Edition (SCID I/P, Version 2.0). New York: New York State Pscyhiatric Institute, Biometrics Research Department; 1995.
• [42]Friis S, Larsen TK, Melle I, Al E: Methodological pitfalls in early detection studies - the NAPE lecture 2002. Acta Psychiatr Scand 2003, 107:3-9.
• [43]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
• [44]American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (Dsm-Iv). 4th edition. Washington DC: American Psychiatric Association; 1994.
• [45]Larsen TK, McGlashan TH, Moe LC: First-episode schizophrenia: I Early course parameters. Schizophrenia Bull 1996, 22(2):241-256.
• [46]Cannon-Spoor HE, Potkin SG, Wyatt RJ: Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982, 8:470-484.
• [47]Strauss JS, Carpenter WT: The prediction of outcome in schizophrenia II Relationships between predictor and outcome variables: a report from the WHO pilot study of schizophrenia. Arch Gen Psychiatry 1974, 31:37-42.
• [48]EMCDDA: 2010 Annual Report on the State of the Drugs Problem in Europe. Lisbon: European monitoring centre for drugs and drug addiction; 2010.
• [49]Johannessen J, McGlashan T, Larsen T, Horneland M, Joa I, Mardal S, Kvebæk R, Friis S, Melle I, Opjordsmoen S, et al.: Early detection strategies for untreated first-episode psychosis. Schizophr Res 2001, 51:39-46.
• [50]Tarrier N, Khan S, Cater J, Picken A: The subjective consequences of suffering a first episode psychosis: trauma and suicide behaviour. Soc Psychiatry Psychiatr Epidemiol 2007, 42:29-35.
• [51]Kavanagh DJ, Young R, White A, Saunders JB, Wallis J, Shockley N, Jenner L, Clair A: A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev 2004, 23:151-155.
• [52]Mordal J, Holm B, Gossop M, Romøren M, Mørland J, Bramness JG: Psychoactive substance use among patients admitted to an acute psychiatric ward: laboratory findings and associations with clinical characteristics. Nord J Psychiatry 2011, 65:208-215.
• [53]Matsumoto T, Kamijo A, Miyakawa Y, Endo K, Yabana T, Kishimoto H, Okudaira K, Iseki E, Sakai T, Kosaka K: Metamphetamine in Japan: the consequences of metamphetamine abuse as a funciton of route of administration. Addiction 2002, 97:809-817.